<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706222</url>
  </required_header>
  <id_info>
    <org_study_id>MISP#57751</org_study_id>
    <nct_id>NCT03706222</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan</brief_title>
  <official_title>The Real World Analysis of Drug-Drug Interactions of Grazoprevir/Elbasvir in Treatment of Chronic Hepatitis C Patients in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Co-morbid diseases often present in a substantial proportion of patients with chronic
      hepatitis C (CHC) and require drugs to treat and control. Grazoprevir/elbavir is metabolized
      by cytochrome P-450 enzyme of liver. Drug-drug interactions (DDIs) are important issue before
      commencing direct acting antiviral agents (DAA) treatment for CHC patients. Few studies from
      Western countries reported that the percentages of DDIs of grazoprevir/elbasvir are
      limited.In Asia, real-world analysis of DDIs of grazoprevir/elbasvir is lacking and needs to
      be clarified.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, retrospective study. Five hospitals in Taiwan and 400 patients
      Patients treated with grazoprevir/elbasvir during August 2017 to July 2018 are candidates of
      study subjects. All the required study information will be recorded with detailed chart
      review.

      DDI will be evaluated by HEP Drug Interactions (www.hep-druginteractions.org) assessment of
      comidications: Category 0: Classification not possible due to lack of information; Category
      1: No clinical interaction possible; Category 2: May require dose adjustment/closer
      monitoring; Category 3: Coadministration not recommended or contraindicated.

      The assessment of DDI will be evaluated and recorded according to the suggested categories,
      the number of patients at risk for a clinically relevant DDI, and the ratio of patients with
      at least one predicted DDI between medication of grazoprevir/elbasvir will be calculated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Actual">February 25, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the potential drug drug interaction of elbasvir/grazoprevor</measure>
    <time_frame>DDI will be assessed before and through the 12 weeks or 16 weeks of elbasvir/grazoprevir treatment</time_frame>
    <description>the ratio of patients with at least one predicted DDI will be analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the comorbid diseases of CHC patients in Taiwan</measure>
    <time_frame>Comorbid diseases will be assessed before elbasvir/grazoprevir treatment.</time_frame>
    <description>Comorbid diseases will be recorded and categorized by involved organ systems before elbasvir/grazoprevir treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>Drug interaction of Elbasvir/Grazoprevir</arm_group_label>
    <description>Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elbasvir/grazoprevir</intervention_name>
    <description>Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.</description>
    <arm_group_label>Drug interaction of Elbasvir/Grazoprevir</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with genotype 1 or 4 hepatitis C virus and treated with
        elbasvir/grazoprevir during August 2017 to July 2018 in Taiwan.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with grazoprevir/elbasvir are candidates of study subjects.

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pin-Nan Cheng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Pin-Nan Cheng</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MK-5172</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03706222/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>May 26, 2020</submitted>
    <returned>June 8, 2020</returned>
    <submitted>June 16, 2020</submitted>
    <returned>July 2, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

